0000950170-24-073851.txt : 20240614
0000950170-24-073851.hdr.sgml : 20240614
20240614180251
ACCESSION NUMBER: 0000950170-24-073851
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240614
FILED AS OF DATE: 20240614
DATE AS OF CHANGE: 20240614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CHESS ROBERT
CENTRAL INDEX KEY: 0001227886
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24006
FILM NUMBER: 241046305
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS
CENTRAL INDEX KEY: 0000906709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943134940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 4154825300
MAIL ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC
DATE OF NAME CHANGE: 19980723
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS
DATE OF NAME CHANGE: 19940303
4
1
ownership.xml
4
X0508
4
2024-06-14
0000906709
NEKTAR THERAPEUTICS
NKTR
0001227886
CHESS ROBERT
C/O NEKTAR THERAPEUTICS
455 MISSION BAY BLVD SOUTH
SAN FRANCISCO
CA
94158
true
false
false
false
true
Common Stock
2024-06-14
4
S
false
19500
1.20
D
255273
D
Common Stock
2100
I
by daughter
Common Stock
2100
I
by son
Common Stock
2100
I
by daughter
This transaction was made pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $1.19 to $1.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for the purposes of Section 16 or for any other purpose.
Mark A. Wilson, Attorney-in-Fact
2024-06-14